MNOVNasdaqPharmaceutical PreparationsFiscal year ends December 31
MEDICINOVA INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.40−0.02 (-1.41%)
Close on Oct 19, 2026
- Market cap
- $68.91M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.17 (+13.82%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
MEDICINOVA INC reported revenue of $920.48K for the twelve months to Jun 30, 2026. Free cash flow was -$9.12M.
Revenue
$920.48K
TTM Q2 2026
Operating income
-$11.85M
TTM Q2 2026
Free cash flow
-$9.12M
TTM Q2 2026
EPS, diluted
-$0.22
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $68.91M
- P/E ratio
- –
- Price to sales
- 74.86
- Price to book
- 1.85
- Dividend yield
- –
- Free cash flow yield
- -13.24%
Fundamentals
- Revenue
- $920.48K
- Net income
- -$10.75M
- EPS, diluted
- -$0.22
- Free cash flow
- -$9.12M
- Book value per share
- $0.76
- Diluted shares
- 49M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$920.48K
Operating income
-$11.85M
Net income
-$10.75M
EPS, diluted
-$0.22
Free cash flow
-$9.12M
Reported periodTrailing twelve months